Evidence map›Paper›PMID 31936341›Full record

ArticleMolecules (Basel, Switzerland)2020

Ultrashort Cationic Lipopeptides-Effect of

Damian Neubauer, Maciej Jaśkiewicz, Marta Bauer, Krzysztof Gołacki, Wojciech Kamysz

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Article
  2. Article
  3. Two EngineeredBiology · 2026
    Article
  4. Article
  5. AMPEC4:Molecules (Basel, Switzerland) · 2025
    Article
  6. Recent innovations and challenges in the treatment of fungal infections.Frontiers in cellular and infection microbiology · 2025
    Review
  7. EndophyticFrontiers in microbiology · 2025
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. In Vitro Activity of Novel Lipopeptides against Triazole-ResistantJournal of fungi (Basel, Switzerland) · 2022
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Damian NeubauerDepartment of Inorganic Chemistry, Faculty of Pharmacy, Medical University of Gdańsk, 80-416 Gdańsk, Poland.
Maciej JaśkiewiczDepartment of Inorganic Chemistry, Faculty of Pharmacy, Medical University of Gdańsk, 80-416 Gdańsk, Poland.
Marta BauerDepartment of Inorganic Chemistry, Faculty of Pharmacy, Medical University of Gdańsk, 80-416 Gdańsk, Poland.
Krzysztof GołackiDepartment of Inorganic Chemistry, Faculty of Pharmacy, Medical University of Gdańsk, 80-416 Gdańsk, Poland.
Wojciech KamyszDepartment of Inorganic Chemistry, Faculty of Pharmacy, Medical University of Gdańsk, 80-416 Gdańsk, Poland.

Funding

Gdański Uniwersytet Medyczny ST-02-0087/07/508
6 · The paper itself

Abstract

Ultrashort cationic lipopeptides (USCLs) are promising antimicrobial agents that hypothetically may be alternatively used to combat pathogens such as bacteria and fungi. In general, USCLs consist of fatty acid chains and a few basic amino acid residues. The main shortcoming of USCLs is their relatively high cytotoxicity and hemolytic activity. This study focuses on the impact of the hydrophobic fatty acid chain, on both antimicrobial and hemolytic activities. To learn more about this region, a series of USCLs with different straight-chain fatty acids (C8, C10, C12, C14) attached to the tripeptide with two arginine residues were synthesized. The amino acid at the

Indexed as

Amino AcidsAnti-Bacterial AgentsCationsFatty AcidsHemolysisHumansHydrophobic and Hydrophilic InteractionsLipopeptidesMicrobial Sensitivity TestsStructure-Activity RelationshipAmino AcidsAnti-Bacterial AgentsCationsFatty AcidsLipopeptidesantimicrobial peptidesbranched fatty acidcationic lipopeptideshydrophobicitylipopeptidesUSCLs

Identifiers

PMID31936341
PMCPMC7024302

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.